Singapore markets closed

Straits Times Index
3,300.04
-3.15(-0.10%)
S&P 500
5,193.18
+12.44(+0.24%)
Dow
38,955.59
+103.32(+0.27%)
Nasdaq
16,363.80
+14.55(+0.09%)
Bitcoin USD
63,499.16
-128.69(-0.20%)
CMC Crypto 200
1,311.58
-53.54(-3.92%)

JNJ Jun 2024 155.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.9000

+0.1500

(+19.74%)

As of 10:37AM EDT. Market open.

Loading interactive chart…

Simply Wall St.
With 71% ownership, Johnson & Johnson (NYSE:JNJ) boasts of strong institutional backing
Key Insights Significantly high institutional ownership implies Johnson & Johnson's stock price is sensitive to their...
GuruFocus.com
Beyond the Balance Sheet: What SWOT Reveals About Shockwave Medical Inc (SWAV)
Insightful Analysis of Shockwave Medical's Position in the Cardiovascular Device Market
Benzinga
Johnson & Johnson Advances Its Two Bladder Cancer Studies, Releases Latest Data
On Sunday, Johnson & Johnson (NYSE:JNJ) ) released updated results from an open-label, multicenter, multi-cohort Phase 1 study of TAR-210 in patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations. TAR-210 is an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib into the bladder. These data were featured at the 2024 American Urological Association (AUA) Annual Meeting. Results featured updated data from Cohort 1 (C1),